Parkinson's Disease Psychosis: A Pharmacist's Update of New Treatment Options

DECEMBER 21, 2016
Jack J. Chen, PharmD, BCPS, BCGP, FASCP, FCCP
This activity is supported by an educational grant from Acadia Pharmaceuticals Inc.

Parkinson's Disease Psychosis: A Pharmacist's Update of New Treatment Options

Faculty
Jack J. Chen, PharmD, BCPS, BCGP, FASCP, FCCP 
Department of Pharmacy Practice College of Pharmacy
Marshall B. Ketchum University Fullerton, California
Movement Disorders Center Department of Neurology Loma Linda, California 

Educational Objectives
After completing this continuing education program, the participant will be able to:
  1. Identify the clinical features and risk factors of Parkinson’s disease psychosis (PDP)
  2. Differentiate the pharmacology, safety, and efficacy of available pharmacologic treatment options for PDP
  3. Explore optimal management strategies for patients with PDP

Target audience: Pharmacists
Type of activity: Application
Release date: December 12, 2016
Expiration date: December 12, 2017
Estimated time to complete activity: 2.0 hours
Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-16-152-H01-P. The activity is available for CE credit through December 12, 2017.

SHARE THIS SHARE THIS
85
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

Pharmacy Times Strategic Alliance
 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.